ABBREVIATION |
DEFINITION AND NOTES |
|---|---|
ACA |
Patient Protection and Affordable Care Act |
AFP |
alpha-fetoprotein |
ALT |
alanine aminotransferase |
AMP |
average manufacturer price |
Anti-HCV |
HCV antibody |
APRI |
AST-to-platelet ratio index |
AST |
aspartate aminotransferase |
AUC |
area under the curve |
AWP |
average wholesale price |
BOC |
boceprevir |
CBC |
complete blood count |
CDC |
Centers for Disease Control and Prevention |
CEA |
cost-effectiveness analysis |
CTP |
Child-Turcotte-Pugh (see below) |
CYP |
cytochrome P450 |
DAA |
direct-acting antiviral |
eGFR |
estimated glomerular filtration rate |
ESRD |
end-stage renal disease |
FDA |
US Food and Drug Administration |
GFR |
glomerular filtration rate |
HBsAG |
hepatitis B virus surface antigen |
HBV |
hepatitis B virus |
HCC |
hepatocellular carcinoma |
HCV |
hepatitis C virus |
ICER |
incremental cost-effectiveness ratio |
IDU |
injection drug use or user |
INR |
international normalized ratio |
MELD |
model for end-stage liver disease |
MSM |
men who have sex with men |
NASH |
nonalcoholic steatohepatitis |
NAT |
nucleic acid testing |
NIH |
National Institutes of Health |
NS3 |
HCV nonstructural protein 3 |
NS5A |
HCV nonstructural protein 5A |
OATP |
organic anion-transporting polypeptide |
PBM |
pharmacy benefit manager |
PCR |
polymerase chain reaction |
P-gp |
P-glycoprotein |
PreP |
preexposure prophylaxis |
PWID |
people who inject drugs |
QALY |
quality-adjusted life-year |
RAS |
resistance-associated substitution |
RBC |
red blood cell(s) |
RBV |
ribavirin |
RGT |
response-guided therapy |
sAg |
surface antigen |
SMV |
simeprevir |
SOF |
sofosbuvir |
SVR12 (or 24 or 48, etc) |
sustained virologic response at 12 weeks (or at 24 weeks, or at 48 weeks, etc) |
TSH |
thyroid-stimulating hormone |
TVR |
telaprevir |
ULN |
upper limit of normal |
USPSTF |
US Preventive Services Task Force |
WAC |
wholesale acquisition costb |
a “List price” for wholesale pharmacies to purchase drugs |
|
Child-Turcotte-Pugh (CTP) Classification of the Severity of Cirrhosis
CLASS A |
CLASS B |
CLASS C |
|
Total Points |
5-6 |
7-9 |
10-15 |
Factor |
1 Point |
2 Points |
3 Points |
Total bilirubin (µmol/L) |
<34 |
34-50 |
>50 |
Serum albumin (g/L) |
>35 |
28-35 |
<28 |
Prothrombin time / international normalized ratio |
<1.7 |
1.71-2.3 |
>2.3 |
Ascites |
None |
Mild |
Moderate to Severe |
Hepatic encephalopathy |
None |
Grade I-II (or supressed with medication) |
Grade III-IV (or refractory) |
Last update: November 6, 2019
